NVNXF
NOVONIX Ltd
$0.1710
-2.29%
No data for this timeframe.
Vol
SEC Reports5
Exchange OTC·Sector Miscellaneous Electrical Machinery, Equipment & Supplies·Inc. C3·CIK 0001859795·Prev Close $0.1750
Recent Activity
Jun 9, 2026
SEC
NOVONIX announced CFO Robert Long will leave in July; Chair Ron Edmonds steps in as Interim CFO while Deputy Chair Rober
6-K — Impact 3/10
May 5, 2026
SEC
NOVONIX Ltd filed a 6-K reporting that Director Michael O'Kronley was granted 5,862,567 performance rights on May 5, 202
6-K — Impact 2/10
Apr 27, 2026
SEC
NOVONIX Ltd filed a 6-K to announce the issuance of 32,566 ordinary fully paid shares on April 27, 2026, resulting from
6-K — Impact 2/10
Analyst Ratings
2Strong Buy
2Buy
1Hold
0Sell
0Strong Sell
Latest Reports
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
5 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 4 neutral. Avg impact: 3.8/10.
NEUTRAL
6-K
3/10
NOVONIX announced CFO Robert Long will leave in July; Chair Ron Edmonds steps in as Interim CFO whil
Jun 9, 2026
NEUTRAL
6-K
2/10
NOVONIX Ltd filed a 6-K reporting that Director Michael O'Kronley was granted 5,862,567 performance
May 5, 2026
NEUTRAL
6-K
2/10
NOVONIX Ltd filed a 6-K to announce the issuance of 32,566 ordinary fully paid shares on April 27, 2
Apr 27, 2026
NEUTRAL
6-K
5/10
NOVONIX held its 2026 Annual General Meeting, reporting progress on synthetic graphite production, i
Apr 15, 2026
BULLISH
6-K
7/10
NOVONIX announced that its Riverside synthetic graphite project in Tennessee has been certified for
Apr 14, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 80% buy across 5 analysts — 2 strong buy, 2 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | -40.8% | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 2 | 2 | 1 | 0 | 0 | 80% | |
| Apr 1, 2026 | 2 | 2 | 1 | 0 | 0 | 80% | |
| Mar 1, 2026 | 2 | 2 | 1 | 0 | 0 | 80% | |
| Feb 1, 2026 | 2 | 2 | 1 | 0 | 0 | 80% | |
| Jan 1, 2026 | 2 | 2 | 1 | 0 | 0 | 80% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.